UroGen Pharma's Upcoming Investor Draw
UroGen Pharma Ltd. (NASDAQ: URGN), a leading biotech company focused on creating advanced solutions for treating urothelial and specialty cancers, has exciting news regarding its participation in several key investor conferences this September.
Wells Fargo Healthcare Conference
The first event is the Wells Fargo Healthcare Conference, set to take place on September 3rd at 2:15 PM ET. The format for this conference will be a fireside chat where UroGen will discuss its pipeline and future plans. This event presents a valuable opportunity for investors to gain insights directly from the leadership team of UroGen Pharma.
Cantor Fitzgerald Global Healthcare Conference
Following that, UroGen Pharma will be participating in the Cantor Fitzgerald Global Healthcare Conference on September 4th at 3:55 PM ET. Like the previous conference, this will also feature a fireside chat format. Investors can expect to hear more about UroGen's innovative approaches to cancer treatment and other company developments.
H.C. Wainwright Annual Global Healthcare Conference
On September 8th at 9:00 AM ET, UroGen will attend the H.C. Wainwright 27th Annual Global Healthcare Conference. This reputable event presents another moment for UroGen to showcase its advancements and future directions in cancer care to potential and current investors.
Access to Conference Replays
For those who cannot attend these conferences live, webcasts will be available through UroGen's Investor Relations section on their website. It is important to note that these replays will be accessible for approximately 90 days following each event, allowing investors to catch up on any missed information.
About UroGen Pharma Ltd.
UroGen Pharma is committed to enhancing the treatment landscape for urothelial and specialty cancers. The company's proprietary RTGel® reverse-thermal hydrogel technology aims to improve the therapeutic profiles of existing cancer drugs, providing better treatment options for patients. Their notable products include approved medications for low-grade upper tract urothelial cancer and recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed to ablate tumors non-surgically, showcasing UroGen's focus on patient-centric innovation.
Investor Relations Contacts
For inquiries, investors can reach out to Vincent Perrone, Senior Director of Investor Relations at UroGen. He is available at vincent.perrone@urogen.com or via phone at 609-460-3588 ext. 1093. For media inquiries, Cindy Romano, Director of Corporate Communications, can be contacted at cindy.romano@urogen.com, or by calling 609-460-3583 ext. 1083.
Frequently Asked Questions
What are the upcoming conferences UroGen Pharma will attend?
UroGen Pharma will attend the Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright Annual Global Healthcare Conference in September.
What is UroGen Pharma's main focus?
UroGen Pharma specializes in developing innovative therapies for urothelial and other specialty cancers, aiming to improve patients' treatment outcomes.
How can I access the conference presentations?
You can access the conference webcasts through the Investor Relations section of UroGen Pharma's website, with replays available for about 90 days.
Who can I contact for investor inquiries?
Investors can reach out to Vincent Perrone, Senior Director of Investor Relations, for any inquiries related to UroGen Pharma.
What innovative technology does UroGen Pharma utilize?
UroGen Pharma's proprietary RTGel® technology is a hydrogel-based platform designed to improve the effectiveness of existing cancer therapies.
